<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics

Abstract

The DECLARE-TIMI 58 trial is expected to provide conclusive data on the effect of treatment with dapagliflozin in addition to standard of care, on CV outcomes in a broad patient population with type 2 diabetes and CVD or MRF for CVD.